Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.

Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, Welch M, Koenig E, David E, Fox T, Makh S, Aldred J, Goodman I, Pepinsky B, Liu Y, Graham D, Weihofen A, Cedarbaum JM.

Mov Disord. 2019 Jun 17. doi: 10.1002/mds.27738. [Epub ahead of print]

PMID:
31211448
2.

The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age.

Vizcarra JA, Sánchez-Ferro Á, Maetzler W, Marsili L, Zavala L, Lang AE, Martinez-Martin P, Mestre TA, Reilmann R, Hausdorff JM, Dorsey ER, Paul SS, Dexheimer JW, Wissel BD, Fuller RLM, Bonato P, Tan AH, Bloem BR, Kopil C, Daeschler M, Bataille L, Kleiner G, Cedarbaum JM, Klucken J, Merola A, Goetz CG, Stebbins GT, Espay AJ; MDS Technology Task Force and the MDS Rating Scales Program Electronic Development Ad-Hoc Committee.

Mov Disord. 2019 May;34(5):676-681. doi: 10.1002/mds.27673. Epub 2019 Mar 22. No abstract available.

PMID:
30901492
3.

A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.

Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM; and The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group.

J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471.

4.

Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.

Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, Marsh G, Auluck PK, Montrasio F, Nitsch RM, Hirst WD, Cedarbaum JM, Pepinsky RB, Grimm J, Weinreb PH.

Neurobiol Dis. 2019 Apr;124:276-288. doi: 10.1016/j.nbd.2018.10.016. Epub 2018 Oct 28.

5.

FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease.

Matthews DC, Lerman H, Lukic A, Andrews RD, Mirelman A, Wernick MN, Giladi N, Strother SC, Evans KC, Cedarbaum JM, Even-Sapir E.

Neuroimage Clin. 2018 Aug 10;20:572-579. doi: 10.1016/j.nicl.2018.08.006. eCollection 2018.

6.

Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials.

Gold M, Amatniek J, Carrillo MC, Cedarbaum JM, Hendrix JA, Miller BB, Robillard JM, Rice JJ, Soares H, Tome MB, Tarnanas I, Vargas G, Bain LJ, Czaja SJ.

Alzheimers Dement (N Y). 2018 May 24;4:234-242. doi: 10.1016/j.trci.2018.04.003. eCollection 2018. Review.

7.

Elephants, Parkinson's Disease, and Proof-of-Concept Clinical Trials.

Cedarbaum JM.

Mov Disord. 2018 May;33(5):697-700. doi: 10.1002/mds.27398. Epub 2018 May 3. No abstract available.

PMID:
29722454
8.

Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic.

Sardi SP, Cedarbaum JM, Brundin P.

Mov Disord. 2018 May;33(5):684-696. doi: 10.1002/mds.27414. Epub 2018 Apr 27. Review.

9.

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem.

Arnerić SP, Cedarbaum JM, Khozin S, Papapetropoulos S, Hill DL, Ropacki M, Rhodes J, Dacks PA, Hudson LD, Gordon MF, Kern VD, Romero K, Vradenburg G, Au R, Karlin DR, Facheris MF, Fitzer-Attas CJ, Vitolo OV, Wang J, Miller BM, Kaye JA.

Nat Rev Drug Discov. 2017 Oct;16(10):736. doi: 10.1038/nrd.2017.153. Epub 2017 Sep 22. No abstract available.

PMID:
28935908
10.

Fletcher H. McDowell, MD, 1923-2017.

Cedarbaum JM, Aisen M, Volpe BT.

Ann Neurol. 2017 Jul;82(1):1-3. doi: 10.1002/ana.24959. Epub 2017 Jul 10. No abstract available.

PMID:
28544007
11.

Item response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials Database.

Bacci ED, Staniewska D, Coyne KS, Boyer S, White LA, Zach N, Cedarbaum JM; Pooled Resource Open-Access ALS Clinical Trials Consortium.

Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3-4):157-67. doi: 10.3109/21678421.2015.1095930. Epub 2015 Oct 16.

PMID:
26473473
12.

Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.

Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM.

JAMA Neurol. 2015 Nov;72(11):1324-33. doi: 10.1001/jamaneurol.2015.0607.

13.

Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB).

Liu E, Luthman J, Cedarbaum JM, Schmidt ME, Cole PE, Hendrix J, Carrillo MC, Jones-Davis D, Tarver E, Novak G, De Santi S, Soares HD, Potter WZ, Siemers E, Schwarz AJ.

Alzheimers Dement. 2015 Jul;11(7):840-9. doi: 10.1016/j.jalz.2015.04.001. Review.

PMID:
26194317
14.

Erratum to: Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology.

Cedarbaum JM, Stephenson D, Rudick R, Carrillo MC, Stebbins G, Kerr D, Heemskerk J, Galpern WR, Kaufmann P, Cella D, Isaac M, Walton MK.

Neurotherapeutics. 2015 Jan;12(1):285. doi: 10.1007/s13311-014-0323-9. No abstract available.

15.

Commonalities and challenges in the development of clinical trial measures in neurology.

Cedarbaum JM, Stephenson D, Rudick R, Carrillo MC, Stebbins G, Kerr D, Heemskerk J, Galpern WR, Kaufmann P, Cella D, Isaac M, Walton MK.

Neurotherapeutics. 2015 Jan;12(1):151-69. doi: 10.1007/s13311-014-0310-1. Erratum in: Neurotherapeutics. 2015 Jan;12(1):285.

16.

E.U./U.S. CTAD Task Force on Alzheimer's Trial Populations for Study.

Cedarbaum JM.

J Prev Alzheimers Dis. 2014;1(2):66-67. doi: 10.14283/jpad.2014.11. No abstract available.

PMID:
29255831
17.

Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects.

Liang E, Garzone P, Cedarbaum JM, Koller M, Tran T, Xu V, Ross B, Jhee SS, Ereshefsky L, Pastrak A, Abushakra S.

Clin Pharmacol Drug Dev. 2013 Apr;2(2):186-94. doi: 10.1002/cpdd.14. Epub 2013 Mar 16.

PMID:
27121673
18.

Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia.

Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA, Anker SD, Rutkove S, Vrijbloed JW, Isaac M, Rolland Y, M'rini C, Aubertin-Leheudre M, Cedarbaum JM, Zamboni M, Sieber CC, Laurent D, Evans WJ, Roubenoff R, Morley JE, Vellas B; International Working Group on Sarcopenia.

J Cachexia Sarcopenia Muscle. 2012 Sep;3(3):181-90. doi: 10.1007/s13539-012-0078-2. Epub 2012 Aug 3.

19.

Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials.

Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, Vellas B; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Feb;9(1 Suppl):S45-55. doi: 10.1016/j.jalz.2011.11.002. Epub 2012 Jun 1.

PMID:
22658286
20.

Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis.

Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA; Neals/Cytokinetics Study Team.

Amyotroph Lateral Scler. 2012 Sep;13(5):430-8. doi: 10.3109/17482968.2012.684214. Epub 2012 May 16.

PMID:
22591195
21.

Mild cognitive impairment: disparity of incidence and prevalence estimates.

Ward A, Arrighi HM, Michels S, Cedarbaum JM.

Alzheimers Dement. 2012 Jan;8(1):14-21. doi: 10.1016/j.jalz.2011.01.002. Review.

PMID:
22265588
22.

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease.

Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM; ELND005-AD201 Investigators.

Neurology. 2011 Sep 27;77(13):1253-62. doi: 10.1212/WNL.0b013e3182309fa5. Epub 2011 Sep 14.

23.

Revision of the criteria for Alzheimer’s disease: A symposium.

DeKosky ST, Carrillo MC, Phelps C, Knopman D, Petersen RC, Frank R, Schenk D, Masterman D, Siemers ER, Cedarbaum JM, Gold M, Miller DS, Morimoto BH, Khachaturian AS, Mohs RC.

Alzheimers Dement. 2011 Jan;7(1):e1-12.

PMID:
21322828
24.

Seeing with new eyes: finding a path to early intervention trials in Alzheimer's disease.

Cedarbaum JM, Crans G, Grundman M.

J Nutr Health Aging. 2010 Apr;14(4):306-9.

PMID:
20306002
25.

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.

Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, Sabbatini P, Mendelson D, Schwartz L, Gettinger S, Psyrri A, Cedarbaum JM, Spriggs DR.

Clin Cancer Res. 2010 Jan 1;16(1):358-66. doi: 10.1158/1078-0432.CCR-09-2103. Epub 2009 Dec 22.

26.

A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.

Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM, Kaiser P, Slakter JS, Haller J, Do DV, Mieler WF, Chu K, Yang K, Ingerman A, Vitti RL, Berliner AJ, Cedarbaum JM, Campochiaro PA.

Ophthalmology. 2009 Nov;116(11):2141-8.e1. doi: 10.1016/j.ophtha.2009.04.030. Epub 2009 Aug 22.

PMID:
19700196
27.

An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema.

Do DV, Nguyen QD, Shah SM, Browning DJ, Haller JA, Chu K, Yang K, Cedarbaum JM, Vitti RL, Ingerman A, Campochiaro PA.

Br J Ophthalmol. 2009 Feb;93(2):144-9. doi: 10.1136/bjo.2008.138271.

PMID:
19174400
28.

Dynamic and quantitative analysis of choroidal neovascularization by fluorescein angiography.

Shah SM, Tatlipinar S, Quinlan E, Sung JU, Tabandeh H, Nguyen QD, Fahmy AS, Zimmer-Galler I, Symons RC, Cedarbaum JM, Campochiaro PA.

Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5460-8.

PMID:
17122137
29.

A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.

Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA; CLEAR-AMD 1 Study Group.

Ophthalmology. 2006 Sep;113(9):1522.e1-1522.e14. Epub 2006 Jul 28.

PMID:
16876249
30.

NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.

Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, Mendell JR.

Neurology. 2005 Sep 13;65(5):681-9.

PMID:
16157899
31.

Neurotrophin-3 improves functional constipation.

Parkman HP, Rao SS, Reynolds JC, Schiller LR, Wald A, Miner PB, Lembo AJ, Gordon JM, Drossman DA, Waltzman L, Stambler N, Cedarbaum JM; Functional Constipation Study Investigators.

Am J Gastroenterol. 2003 Jun;98(6):1338-47.

PMID:
12818279
32.

Disease status and use of ventilatory support by ALS patients. BDNF Study Group.

Cedarbaum JM, Stambler N.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2001 Mar;2(1):19-22.

PMID:
11465928
33.

Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans.

Coulie B, Szarka LA, Camilleri M, Burton DD, McKinzie S, Stambler N, Cedarbaum JM.

Gastroenterology. 2000 Jul;119(1):41-50.

PMID:
10889153
34.

A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials.

Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM.

J Neurol Sci. 1999 Oct 31;169(1-2):118-25.

PMID:
10540019
35.

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A.

J Neurol Sci. 1999 Oct 31;169(1-2):13-21.

PMID:
10540002
36.

Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat.

Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, Zlotchenko E, Nguyen T, Garcia K, Tonra JR, Stambler N, Cedarbaum JM, Bodine SC, Lindsay RM, DiStefano PS.

Ann Neurol. 1998 Jan;43(1):46-55.

PMID:
9450768
37.

Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group.

Stambler N, Charatan M, Cedarbaum JM.

Neurology. 1998 Jan;50(1):66-72.

PMID:
9443459
38.
39.

Stability of levodopa/carbidopa solutions.

Cedarbaum JM.

Mov Disord. 1997 Jul;12(4):625. No abstract available.

PMID:
9251095
40.

Endogenous NGF and CNTF levels in human peripheral nerve injury.

Anand P, Terenghi G, Birch R, Wellmer A, Cedarbaum JM, Lindsay RM, Williams-Chestnut RE, Sinicropi DV.

Neuroreport. 1997 May 27;8(8):1935-8.

PMID:
9223080
41.

Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial).

Penn RD, Kroin JS, York MM, Cedarbaum JM.

Neurosurgery. 1997 Jan;40(1):94-9; discussion 99-100.

PMID:
8971830
42.

Re: Pharmacokinetics and pharmacodynamics of rHCNTF in rodents.

Cedarbaum JM, DeStefano PS, Lakings DB, Lindsay RM.

Ann Neurol. 1996 Apr;39(4):552-4. No abstract available.

PMID:
8619536
43.

Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease.

Ikeda K, Klinkosz B, Greene T, Cedarbaum JM, Wong V, Lindsay RM, Mitsumoto H.

Ann Neurol. 1995 Apr;37(4):505-11.

PMID:
7717687
44.

Regional changes of ciliary neurotrophic factor and nerve growth factor levels in post mortem spinal cord and cerebral cortex from patients with motor disease.

Anand P, Parrett A, Martin J, Zeman S, Foley P, Swash M, Leigh PN, Cedarbaum JM, Lindsay RM, Williams-Chestnut RE, et al.

Nat Med. 1995 Feb;1(2):168-72.

PMID:
7585015
45.

Histometric effects of ciliary neurotrophic factor in wobbler mouse motor neuron disease.

Ikeda K, Wong V, Holmlund TH, Greene T, Cedarbaum JM, Lindsay RM, Mitsumoto H.

Ann Neurol. 1995 Jan;37(1):47-54.

PMID:
7818257
46.

Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF.

Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM.

Science. 1994 Aug 19;265(5175):1107-10.

PMID:
8066451
47.

The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease.

Mitsumoto H, Ikeda K, Holmlund T, Greene T, Cedarbaum JM, Wong V, Lindsay RM.

Ann Neurol. 1994 Aug;36(2):142-8.

PMID:
8053649
48.

The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.

Lindsay RM, Altar CA, Cedarbaum JM, Hyman C, Wiegand SJ.

Exp Neurol. 1993 Nov;124(1):103-18. Review.

PMID:
8282068
49.

The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses.

Woodward WR, Olanow CW, Beckner RM, Hauser RA, Gauger LL, Cedarbaum JM, Nutt JG.

Neurology. 1993 Sep;43(9):1704-8.

PMID:
8414016
50.

Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.

Guttman M, Léger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A.

Mov Disord. 1993 Jul;8(3):298-304.

PMID:
8341294

Supplemental Content

Loading ...
Support Center